Article
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
PLoS medicine - 1 Oct 2007
Costa Daniel B, Halmos Balázs, Kumar Amit, Schumer Susan T, Huberman Mark S, Boggon Titus J, Tenen Daniel G, Kobayashi Susumu
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR) mutations are present in the majority of patients with non-small cell lung cancer (NSCLC) responsive to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib. These EGFR-dependent tumors eventually become TKI resistant, and the common secondary T790M mutation accounts for half the tumors with acquired resistance to gefitinib. However, the key...
Topics
- Antineoplastic Agents
- Apoptosis
- Apoptosis Regulatory Proteins
- Bcl-2-Like Protein 11
- Carcinoma, Non-Small-Cell Lung
- Cell Line, Tumor
- ErbB Receptors
- Gefitinib
- Humans
- Lung Neoplasms
- Membrane Proteins
- Mutation
- Protein Kinase Inhibitors